quietly-emerging disease

No Image

A Jeff Bezos-backed startup just inked a deal with $84 billion biotech Gilead to make drugs for a troubling and increasingly common disease

Pharmaceutical giant Gilead is teaming up with Silicon Valley startup Insitro to develop better drugs for a quietly emerging disease called NASH. Short for non-alcoholic steatohepatitis, NASH can lead to liver failure and is estimated to affect some 16 million Americans. Insitro is led by the former chief computing officer of Google life-extension spinoff Calico.…